BMO Sees Favorable Risk/Reward for Horizon Pharma (HZNP) Ahead of phase 3 Data for Actimmune in FA

November 28, 2016 6:56 AM EST
Get Alerts HZNP Hot Sheet
Price: $16.80 -0.36%

Rating Summary:
    13 Buy, 2 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade HZNP Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

BMO Capital analyst Gary Nachman sees favorable risk/reward for Horizon Pharma (NASDAQ: HZNP) into Phase 3 data for Actimmune in Friedreich's Ataxia (FA).

Nachman commented, "ased on feedback from ataxia specialists that we include in the note and considering how HZNP designed the Phase 3, we continue to believe there is a 50% probability of success with the top-line data expected in late December. But given our upside/downside scenarios for how we expect the stock to trade as well as our assessment of the fundamental valuation, we continue to believe that risk/reward for owning HZNP stock into this event is favorable."

The firm maintained an Outperform rating and price target of $29 on HZNP.

For an analyst ratings summary and ratings history on Horizon Pharma click here. For more ratings news on Horizon Pharma click here.

Shares of Horizon Pharma closed at $21.49 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

BMO Capital

Add Your Comment